Diabetes Drugs May Cut Epilepsy Risk

A new study indicates a potential link between GLP-1 drugs and a reduced risk of epilepsy in people diagnosed with type 2 diabetes. These medications mimic the GLP-1 hormone, aiding blood sugar control, appetite regulation, and digestion. The research, published in the journal Neurology, analyzed a U.S. health database, tracking individuals newly diagnosed with type 2 diabetes who were prescribed either GLP-1 receptor agonists or DPP-4 inhibitors.

The observational study followed over 450,000 individuals for at least five years. Findings revealed that users of GLP-1 drugs experienced a slightly lower incidence of epilepsy compared to those taking DPP-4 inhibitors. After adjusting for various health factors, GLP-1 users demonstrated a 16% reduction in epilepsy risk, with semaglutide showing the most significant protective effect.

While these findings are promising and suggest potential neurological benefits beyond glycemic control, researchers emphasize the need for larger, randomized controlled trials to confirm the link. The study acknowledges limitations, including its retrospective nature and the exclusion of newer dual-agonist drugs. Epilepsy affects millions globally, and diabetes is a known risk amplifier.